Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Table 2 Baseline characteristics, n (%)

Characteristic	Total	F	R	FP	RP	P value
Patients	313	70	67	95	81
Median age (range)	55 (21-88)	55 (29-88)	57 (29-79)	54 (22-81)	54 (21-83)
Age group						0.895
< 65 yr	251 (80.2)	54 (77.1)	55 (82.1)	77 (81.1)	65 (80.2)
≥ 65 yr	62 (19.8)	16 (22.9)	12 (17.9)	18 (18.9)	16 (19.8)
Sex						0.476
Male	171 (54.6)	37 (52.9)	32 (47.8)	57 (60.0)	45 (55.6)
Female	142 (45.4)	33 (47.1)	35 (52.2)	38 (40.0)	36 (44.4)
ECOG						0.189
0-1	281 (89.8)	59 (84.3)	60 (89.6)	85 (89.5)	77 (95.1)
2	32 (10.2)	11 (15.7)	7 (10.4)	10 (10.5)	4 (4.9)
Primary tumor location						0.335
Left	238 (76.0)	51 (72.9)	56 (83.6)	73 (76.8)	58 (71.6)
Right	75 (24.0)	19 (27.1)	11 (16.4)	22 (23.2)	23 (28.4)
Status of the primary tumor						0.289
Resected	248 (79.2)	53 (75.7)	53 (79.1)	72 (75.8)	70 (86.4)
Unresected	65 (20.8)	17 (24.3)	14 (20.9)	23 (24.2)	11 (13.6)
RAS mutation status1						0.934
Wild-type	98 (31.3)	23 (32.9)	22 (32.8)	30 (31.6)	23 (28.4)
Mutation	144 (46.0)	30 (42.9)	35 (52.2)	42 (44.2)	37 (45.7)
Unknown	71 (22.7)	17 (24.2)	10 (15.0)	23 (24.2)	21 (25.9)
BRAF mutation status1						0.233
Wild-type	222 (70.9)	50 (71.4)	55 (82.1)	65 (68.4)	52 (64.2)
Mutation	20 (6.4)	3 (4.3)	2 (3.0)	7 (7.4)	8 (9.9)
Unknown	71 (22.7)	17 (24.3)	10 (14.9)	23 (24.2)	21 (25.9)
Site of metastases
Liver	178 (56.9)	40 (57.1)	35 (52.2)	53 (55.8)	50 (61.7)	0.703
Lung	174 (55.6)	43 (61.4)	40 (59.7)	45 (47.4)	46 (56.8)	0.254
Number of metastatic sites						0.060
< 3	206 (65.8)	48 (68.6)	50 (74.6)	64 (67.4)	44 (54.3)
≥ 3	107 (34.2)	22 (31.4)	17 (25.4)	31 (32.6)	37 (45.7)
Prior treatment lines
2	188 (60.1)	40 (57.1)	40 (59.7)	53 (55.8)	55 (67.9)	0.384
> 2	125 (39.9)	30 (42.9)	27 (40.3)	42 (44.2)	26 (32.1)
Previous treatment agents
Fluoropyrimidine	313 (100.0)	70 (100.0)	67 (100.0)	95 (100.0)	81 (100.0)	> 0.999
Irinotecan	280 (89.5)	61 (87.1)	61 (91.0)	82 (86.3)	76 (93.8)	0.360
Oxaliplatin	297 (94.9)	68 (97.1)	62 (92.5)	88 (92.6)	79 (97.5)	0.304
Anti-VEGF antibody	270 (86.3)	65 (92.9)	52 (77.6)	83 (87.4)	70 (86.4)	0.075
Anti-EGFR antibody	56 (17.9)	10 (14.3)	15 (22.4)	15 (15.8)	16 (19.8)	0.569

¹Patients with unknown status of KRAS and BRAF V600E were not included in the analysis.

R: Regorafenib; RP: Regorafenib plus programmed death-1 inhibitor; F: Fruquintinib; FP: Fruquintinib plus programmed death-1 inhibitor; ECOG: Eastern cooperative oncology group.